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Abstract An ODE model introduced by Gyllenberg and Webb (1989) de-
scribes tumour growth in terms of the dynamics between proliferating and
quiescent cell states. The passage from one state to another and vice versa is
modelled by two functions ro and ri depending on the total tumour size. As
these functions do not represent any observable quantities, they have to be
identified from the observations.
In this paper we show that there is an infinite number of pairs (ro, ri) corre-
sponding to the same solution of the ODE system and the functions (ro, ri)
will be classified in terms of this equivalence. Surprisingly, the technique used
for this classification permits a uniqueness proof of the solution of the ODE
model in a non-Lipschitz case.
The reasoning can be widened to a more general setting including an extension
of the Gyllenberg-Webb model with a nonlinear birth rate. The relevance of
this result is discussed in a preclinical application scenario.
Keywords Tumour Growth · Quiescence · Parameter identifiability
Mathematics Subject Classification (2000) 92C50 · 34A12 · 34A55
1 Introduction
Cancer is a disease of abnormal tissue growth induced by a series of growth-
promoting genetic changes (Hanahan andWeinberg, 2011). It is a leading cause
of death worldwide (WHO, 2012). Crucial among the many difficulties in can-
cer treatment is the existence of a subpopulation of cancer cells inherently more
resistant to many types of therapy: the quiescent cells (Alarcon and Jensen,
2011; Hittelman et al, 2010; Mellor et al, 2005). Quiescence is a reversible state
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of nondivision that is functionally different from cell cycle arrest as it can be
prolonged and exhibits some characteristic gene expression patterns (Coller
et al, 2006; Coller, 2011). Cancerous cells are known to undergo quiescence
under environmental stress like hypoxia and glucose deficiency, which is com-
monly the case due to poor and aberrant tumour vascularisation, or during
therapy application (Gardner et al, 2001; Hanahan and Weinberg, 2011; Liu
et al, 2011). When environmental conditions are favourable, quiescent cancer
cells can re-enter the cell cycle. In this way, quiescence contributes to therapy
failure and recurrence of the disease.
As tumour cells are principally characterised by their rapid and ongoing di-
vision, many anticancer agents operate on dividing cells, either specifically
during DNA synthesis and mitosis or in a phase-nonspecific manner (e.g. ra-
diotherapy). Naturally, phase-specific anticancer drugs have no effect on non-
cycling cells. Beyond that, the tumour microenvironment, and thus quiescence
induced by environmental stress, has shown to be associated with resistance to
phase-nonspecific agents, including radiotherapy, chemotherapy and gene ther-
apy (Redmond et al, 2008; Tredan et al, 2007; Mellor et al, 2005; Wallbaum
et al, 2009). Strategies to circumvent this resistance by reactivating quiescent
cells are an active field of current research (Kyle et al, 2012).
Tumour cell proliferation measures by immunohistochemical techniques, no-
tably the Ki67 antibody MIB-1, are well established (Brown and Gatter, 2002;
Colozza et al, 2005). More recently, an in vivo following of cell proliferation
in murine models has become possible. High-resolution measurements can be
obtained in vivo by combining gene therapy and SPECT (single-photon emis-
sion computed tomography) imaging (Franken et al, 2010; Richard Fiardo et al,
2012), see Figure 1. These new measurement instruments calls for a review of
mathematical models distinguishing between proliferating and quiescent cell
states and invite to critically analyse their applicability, ultimately aiming to
shed light on the mechanisms inherent in the dynamics between proliferating
and quiescent cells that lead to tumour progression or tumour regression un-
der different therapeutic regimes. We will focus on models relevant for SPECT
imaging of proliferating cells.
The usage of mathematical growth models has yielded important contributions
to solid tumour growth research in the last decades (Araujo and McElwain,
2004). Amongst the many approaches, minimally parametrised models, aim-
ing at reproducing the observed phenomena in a previously defined setting
without integrating all the underlying biological mechanisms explicitly, play a
prominent role. The main interest of such models is that the small number of
parameters included in such models results in less complex numerical simula-
tions and an easier parameter identification.
The oldest and perhaps most cited phenomenological tumour growth model is
the Gompertzian growth model, exhibiting an exponential increase of tumour
volume at early stages and a subsequent deceleration with tumour volume con-
verging to a maximal value, the carrying capacity (Laird, 1964). The Gompertz
model has also been integrated in more complex tumour growth models (Iwata
et al, 2000; Hahnfeldt et al, 1999). However, there is nothing unique about the
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Gompertz model. As was already pointed out by Feller (1939), different mod-
els having such S-shaped (sigmoidal) solutions can fit data equally well. See
for example Hart et al (1998) and Simeoni et al (2004) for some alternative
phenomenological models used to describe tumour growth.
Numerous models distinguish between proliferating and quiescent cells (and
possibly other effects) (Spinelli et al, 2006; Smallbone et al, 2008; Ubezio and
Cameron, 2008), among them a model established by Gyllenberg and Webb
(1989) (in the following referred to as the Gyllenberg-Webb model). This model
is based on the coupled dynamics between proliferating and quiescent cells, re-
alised by two passage rates, from proliferating to quiescent and vice versa. For
the modelling of quiescence, the Gyllenberg-Webb model is exemplary as it is
a minimal approach while having mechanistic components. Amongst others,
D’Onofrio et al (2011) have studied this model, looking for compatibility with
certain scalar ODE models. This point will be further elaborated in Section 3.
In view of the precise in vivo imaging techniques of proliferating cells avail-
able, the call for an applicability study of the Gyllenberg-Webb model arises
naturally, one of its centrepieces being a parameter identifiability study.
In the following section, the model established by Gyllenberg and Webb will be
presented and their mathematical analysis will briefly be recapitulated. Sec-
tion 3 covers the parameter identifiability problem for the Gyllenberg-Webb
model. In particular, an explicit equivalence relation will be established that
groups the passage rates corresponding to the same solutions of the ODEs.
Interestingly, this approach will permit a uniqueness proof of these solutions
for non-Lipschitz passage rates. In Section 4, the reasoning will be generalised
to a larger class of ODEs containing an extended form of the Gyllenberg-Webb
model with a nonlinear birth rate. Finally, the consequences for the applica-
bility of the Gyllenberg-Webb model is discussed.
2 The Gyllenberg-Webb model
The generic ODE model proposed by Gyllenberg and Webb (1989) distin-
guishes between proliferating (P ) and quiescent (Q) cells and is based on a
dynamic state change between these two classes. Proliferating cells reproduce
and die with a specific growth rate (birth rate minus death rate) b > 0 and
can become quiescent. Quiescent cells cannot reproduce but can become pro-
liferating again. Death of quiescent cells is described by a mortality parameter
µ > 0. The total tumour size N is the sum of proliferating and quiescent
cells. Thus, the model is given by the following system of ordinary differential
equations (ODE):
P ′(t) = [b− ro(N(t))]P (t) + ri(N(t))Q(t), (1)
Q′(t) = ro(N(t))P (t)− [ri(N(t)) + µ]Q(t), (2)
N(t) = P (t) +Q(t), (3)
P (0) = P0 > 0, Q(0) = Q0 > 0. (4)
4 Niklas Hartung
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Fig. 1: SPECT images of colorectal human cancer cells (HT-29) that were mod-
ified to express a iodine transportation protein and implanted in an immun-
odeficient mouse. Iodine 123 has been used as a radiotracer. Images obtained
from T. Pourcher of the TIRO laboratory in Nice (France), with permission.
In the outer layers of the tumour, an important accumulation of the radio-
tracer has been registered, which corresponds to the proliferating cancer cells.
The radiotracer does not accumulate in quiescent cells and they are therefore
indistinguishable from dead cells.
The functions ro and ri describe the passage between the two states and are
supposed to depend on the total tumour size. The function ro is assumed
continuously increasing and ri is assumed continuously decreasing.
Gyllenberg and Webb’s results will be stated in an abbreviated form, and we
are going to complement them thereafter. We refer to Gyllenberg and Webb
(1989) for their rigorous and detailed discussion.
Proposition 1 (The case ri ≡ 0 and µ = 0) Suppose that lim
N→+∞
ro(N) >
b, ri ≡ 0 and µ = 0. Then N = P + Q is increasing and reaches a plateau







P (t) = 0.
Proposition 2 (The case ri(N) > li > 0 and µ = 0) Suppose that ri(N) >




+∞. If ro is bounded, then lim
t→+∞
P (t) = +∞. If ro is unbounded, then
lim sup
t→+∞
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Proposition 3 (The case ri(N) > li > 0 and µ > 0) Suppose ri(N) >
li > 0 for all N > 0 and µ > 0. If the tendency to become quiescent is suffi-
ciently low in small tumours (N small) and sufficiently high in large tumours
(N large), then there exists a unique nontrivial equilibrium that is globally










Gyllenberg and Webb remarked that in all of these cases their hypotheses
implied a diminishing of the growth fraction P
N
and gave two examples of
functions ro with ri ≡ 0 such that the total tumour size N satisfies the logistic
and Gompertz equation, respectively.
3 Equivalent parameter sets and uniqueness of solutions in the
Gyllenberg-Webb model
If we want to evaluate the quantitative performance of the Gyllenberg-Webb
model, the rates ro and ri need to be specified. However, it is difficult to justify
a particular choice for these functions as they do not represent any observable
quantities. It is therefore interesting to study the identifiability problem of the
parameters from given solutions (P,Q) of the ODE system (1-4), which are
measurable.
Hypothesis (H) In this section, we will assume that b > 0, µ = 0,
ro is a positive nondecreasing continuous function and that ri is a




This setting allows an easier presentation of the principal result but it has also
a biological significance. In subcutaneous tumours xenografted in mice, an of-
ten used experimental model, the dead tissue is often completely surrounded
by tumour cells (Ribba et al, 2011). It is therefore reasonable to consider the
dead tissue as a contribution to the total tumour volume, which can be done
by posing µ = 0. If we want the model to reproduce the “recruiting” of quies-
cent cells during a therapy, we need to consider a passage rate ri which is not
identically zero. Note that ri is allowed to tend to zero at infinity and there can
even exist NL > 0 such that ri(NL) = 0 (and thus ri|[NL,+∞) ≡ 0), a case that
was not included in the analysis of Gyllenberg and Webb. As will be shown
in this section, any reasonable ODE model for tumour growth depending only
on total tumour size, like the Gompertzian and the logistic growth model,
can be reproduced by a variety of parameter sets (b, ro, ri), with ri non identi-
cally zero but vanishing in NL > 0. The case µ > 0 will be covered in Section 4.
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3.1 Direct problem
Before analysing the identifiability problem let us state two results on the
direct problem for the sake of completeness:
Proposition 4 (Global existence and positivity of solutions of (1-4))
Let P0 > 0, Q0 > 0, b > 0, µ > 0, ro continuous, nondecreasing and positive, ri
continuous, nonincreasing and non-negative. Then there is at least one solution
(P,Q) of (1-4), defined for all times t ∈ [0,+∞). All solutions are positive for
t ∈ (0,+∞).
Proof A detailed proof can be found in Hartung (2011). Positivity can be es-
tablished with standard manipulations of equations (1-4) and global existence
uses the explosion theorem for finite times of existence (Amann and Escher,
2006). ⊓⊔
The asymptotics of N and P have been studied by Gyllenberg and Webb
in different scenarios, including the one specified by the hypotheses (H) with
a technical restriction ri > C > 0. We will propose a different proof that is
valid for lim
N→+∞
ri(N) = 0 as well and in which the line of argument is much
simpler.
Proposition 5 (Asymptotics) Let us suppose that hypothesis (H) holds and
let us note
NL := inf{N > 0 : ri(N) = 0}, N∗ := lim
t→+∞
N(t).
Then we have the following:
NL = +∞⇒ N∗ = +∞, NL < +∞⇒ N∗ < +∞,
lim inf
t→∞
P (t) > lim inf
N→∞
ri(N)N
ro(N) + ri(N)− b , (5)
lim sup
t→∞
P (t) 6 lim sup
N→∞
ri(N)N
ro(N) + ri(N)− b . (6)
Proof The asymptotic behaviour of N can be shown with standard techniques
(see Hartung, 2011; Gyllenberg and Webb, 1989, for further details). Let us
address the asymptotic behaviour of P . For the limsup estimation let us
consider a sequence tk that tends to infinity such that
lim
k→+∞
P (tk) = lim sup
t→+∞
P (t), lim inf
k→+∞
P ′(tk) ∈ [0,+∞].
Such a sequence exists for any inferiorly bounded differentiable function. We
still denote by tk a subsequence for which lim
k→+∞
P ′(tk) ∈ [0,+∞] exists and
we rewrite (1) replacing Q by N − P :
N(tk)ri(N(tk))
ro(N(tk)) + ri(N(tk))− b = P (tk) + P
′(tk)V (tk),
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with V (tk) :=
1
ro(N(tk))+ri(N(tk))−b
and k sufficiently large such that ro(N(tl)+
ri(N(tl)) > b for all l > k. We remark that ro(N(tl)+ri(N(tl))−b is uniformly
positive by hypothesis (H), and up to passing to a maximising subsequence
(still denoted tk) of V (tk) we can assume that lim
k→+∞
V (tk) ∈ [0,+∞) exists.












ro(N) + ri(N)− b > limk→+∞
N(tk)ri(N(tk))
ro(N(tk)) + ri(N(tk))− b .
This yields (6). Similarly, inequality (5) can be obtained with a minimis-
ing sequence satisfying lim sup
k→+∞
P ′(tk) 6 0 (considering separately the case
lim inf
t→+∞
P (t) = +∞). ⊓⊔
3.2 Main result
The analysis in this section is founded on the following basic consideration:
As we assume that µ = 0, equations (1-2) imply N ′ = bP hence N ′′ = bP ′. By
inserting these two equations in (1), one obtains the second order equation
N ′′ = (b− ro(N)− ri(N))N ′ + bNri(N). (7)
We will now impose a first order ODE growth N ′ = f(N) on the total tu-
mour size N = P + Q to gain insight on the nature of the passage rates
ro and ri. At this point, it may seem unreasonable to add a constraint to
the Gyllenberg-Webb model, but we will see that a large variety of passage
rates can be characterised in this way. The constraint can be thought of as an
empirical macroscopic growth model fitting data from preclinical or clinical
observations.
In the case of the Gompertz growth model, this question has been studied by
Kozusko and Bajzer (2003). Moreover, D’Onofrio, Fasano, and Monechi (2011)
have introduced a notion of compatibility essentially equivalent to the follow-
ing definition. The present study is yet not redundant as the objectives are
different: The mentioned articles aimed at the fusion of certain ODE models
with the Gyllenberg-Webb model, whereas the present study is focussed on
the applicability of the Gyllenberg-Webb model, a question not addressed in
the previous studies. The following sections and especially the discussion will
further clarify this important difference.
By inserting N ′ = f(N) in (7), one obtains
f ′(N)f(N) = (b− ro(N)− ri(N))f(N) + bri(N)N,
which motivates the following definition:
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Definition 1 (Compatibility equation)
For f ∈ C1((N0, N∗),R+) ∩ C0([N0, N∗),R+), we call
f ′(n)f(n) = (b− ro(n)− ri(n))f(n) + bri(n)n, (8)
compatibility equation and we say that the parameters (b, ro, ri) are compat-
ible with the function f if (8) holds on (N0, N
∗) and if f(N0) = bP0.
With this definition, we can now state the main result.
Theorem 1 Let b > 0, ro continuous and increasing, ri continuous and de-
creasing.
– There is a unique solution (P,Q) of the Gyllenberg-Webb model (1-4)
– There is a unique function f(b,ro,ri) ∈ C1([N0, N∗),R+) that satisfies the
compatibility equation (8) and the condition f(b,ro,ri)(N0) = bP0. We will
call f(b,ro,ri) the associated function.
– N = P +Q is the unique solution of N ′(t) = f(b,ro,ri)(N(t)).
Remark 1 Observe that the proof technique also yields uniqueness of the so-
lutions P and Q of (1-4) when ro and ri are not supposed locally Lipschitz
continuous.
Proof (Proof of Theorem 1.)
– Associated function.
Let us start by considering equation (8). With the change of variables
g = f2 and by writing a1(n) = 2(b− ro(n)− ri(n)) and a2(n) = 2bnri(n),






the existence and uniqueness of which is assured by the Picard-Lindelo¨f
theorem as long as g does not vanish. Let N˜ = sup{n > N0 : g > 0 on
(N0, n)}. Thus, on (N0, N˜) the function f(b,ro,ri) :=
√
g is well defined and
the property
N˜ < +∞⇒ lim
n→N˜
f(n) = 0
follows as a direct consequence of the definition of N˜ using the fact that g is
continuous. Note that this result could be established for f directly, but it
is the upper change of variables which will be needed for the generalisation
in Section 4.
– N is solution of the ODE.
Let (P,Q) be a solution of (1-4). Global existence and positivity have been
established in Proposition 4. Recall that N = P +Q satisfies (7) and that
N∗ := lim
t→+∞
N(t). As N ′ = bP > 0, we can define h(n) := N ′(N−1(n)) on
[N0, N
∗). We have h(N(t)) = N ′(t) and h′(N(t))h(N(t)) = N ′′(t). Thus,
on (N0, N
∗), h is a solution of (8), hence h ≡ f(b,ro,ri) on (N0,min(N˜ ,N∗)).
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– N˜ = N∗ holds.
We have f(b,ro,ri)(N(t)) = bP (t) > 0 for all t > 0, hence N˜ > N
∗. On the





N ′(t) = 0
since N ′ = bP > 0, hence N˜ = N∗.
– Uniqueness of solutions (P,Q).
For every solution N = P +Q, we have N ′(t) = f(b,ro,ri)(N(t)) on [0,+∞).
As f(b,ro,ri) is locally Lipschitz, N can be determined unambiguously from
f(b,ro,ri). Finally, P =
N ′
b
and Q = N − P are determined unambiguously
from N . ⊓⊔
Theorem 1 allows for an explicit characterisation of the parameters corre-
sponding to the same solutions of the ODE:
Definition 2 (Parameter equivalence) For given b > 0, P0 and Q0, we
can define an equivalence relation in the set
{(ro, ri) ∈ C0((N0,+∞))2 : ro increasing and ri decreasing }:
(r1o, r
1
i ) ∼ (r2o, r2i ) ⇔ N∗1 = N∗2 and f(b,r1o,r1i ) ≡ f(b,r2o,r2i ),
where the functions on the right-hand side are the functions associated to
(b, r1o, r
1




i ), respectively, as defined in the preceding theorem. This
proves their existence and uniqueness, as well as the fact that the solutions
(P,Q) coincide if and only if they are in the same equivalence class.
3.3 Consequences
Corollary 1 (Non-identifiability and descriptive flexibility) Let P0 >
0, Q0 > 0 and N0 = P0+Q0. Suppose that f ∈ C1((N0, N∗),R+) with N∗ =∞
or lim
N→N∗
f(N) = 0. Then there are b > 0 and infinitely many passage rates
(ro, ri) continuous such that the associated solutions of the Gyllenberg-Webb
model (P,Q) coincide and such that the total tumour size N = P + Q is
the solution of the corresponding ODE model N ′ = f(N), N(0) = N0. If f
′
is decreasing (e.g. Gompertz model, logistic model, etc.), there exist infinitely
many couples (ro, ri) with ro increasing and ri decreasing.
Proof Define b > 0 by the relation f(N0) = bP0 and let ri be any nonnega-
tive continuous function. Then we solve the compatibility equation (8) for ro
such that f ≡ f(b,ro,ri) (that is, ro = b− f ′ + ri(bN/f − 1)). Every parameter
set (ro, ri) constructed in this manner lies in the same equivalence class, and
Theorem 1 yields the result.
If f ′ is decreasing, the preceding construction with ri ≡ 0 yields an increasing
function ro. It can now easily be seen that if ri is small enough (and decreas-
ing), the corresponding function ro is still increasing. ⊓⊔
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Remark 2 In the previous proof, monotony was shown for small perturbations
of ri ≡ 0. In the following corollary, this is shown for arbitrarily big perturba-
tions in a special case.
Corollary 2 (Parameter estimation with four unknown parameters.)
Let (P,Q) be a solution of (1-4) such that the total tumour size N = P + Q
follows the logistic equation N ′ = f(N) = κN(1 − N/θ) with κ, θ > 0 and
b > 0 such that f(N0) = bP0.
Then the parameter estimation problem
Calculate α > 0, β > 0, γ > 0, δ > 0 such that the solutions
(Pα,β,γ,δ, Qα,β,γ,δ) of (1-4) associated to the functions ro(n) = α + βn
and ri(n) = (γ − δn)+ minimise the functional
J(α, β, γ, δ) := ||(Pα,β,γ,δ, Qα,β,γ,δ)− (P,Q)||
is ill-posed.









κ(1− n/θ) − 1
)
ri(n).
Hence, for all s > 0, the functions rso(n) = (1 + s)(κ − b) + (2+s)κθ n and





are equivalent with associated function f(n) = κn(1−n/θ)
(cf. Figure 2). ⊓⊔
Remark 3 In the previous example, the total tumour size N followed the logis-
tic curve. The same reasoning can be used for other sigmoidal growth curves,
but the parametrisation of ro and ri becomes more complicated in this case.
4 A generalisation of Theorem 1
To a certain extent, the methods used in the preceding section can be gener-
alised.
4.1 Statement
Consider the following system of ODEs:{
x′ = F1(x, y),
y′ = F2(x, y),
(9)
along with the initial conditions x(0) = x0 > 0, y(0) = y0 > 0.
Theorem 2 Let F1 ∈ C0(R+ × R+) locally Lipschitz with respect to x and
F2 ∈ C2(R+ × R+). Suppose that F2 > 0 and that there is a function Φ ∈
C0,1(R+×R+) such that any solution (x, y) of (9) satisfies x = Φ(y, y′). Then
there is exactly one local solution of (9).
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(a) Passage rates ro. (b) Passage rates ri
Fig. 2: An example of equivalent passage rates: the three pairs (ro, ri) are
compatible with the same logistic growth model imposed on the total tu-
mour size. Thus, the solutions (P,Q) of (1-4) coincide. Passage rates: r1o(N) =
0.0854 + 4 · 10−9N , r2o(N) = 0.128 + 4.573 · 10−9N − 10−17N2, r3o(N) =
0.128+5 · 10−9N , r1i ≡ 0, r2i (N) = 10−17(N − 108) and r3i (N) = 0.1− 10−9N .
The passage rates rjo have been calculated from r
j
i , j = 1, 2, 3 and the logis-
tic growth function f(N) = 0.2N(1 − N/108) via relation (8). Initial values:
P0 = 7 · 104, Q0 = 3 · 104.
Proof Let (x, y) be a solution of (9). By virtue of our hypotheses, there is a










(Φ(y, y′), y). (10)
As y′ = F2(x, y) > 0, y is invertible. Let f := y
′(y−1) ∈ C1(R+). We replace














where y = y(t). Note that (11) is an autonomous equation. As the function on
















g(y0) = F2(x0, y0) > 0
(12)
has a unique solution g˜ ∈ C1((y0, y∗),R+) where y∗ = +∞ or g(y∗) = 0. Let
us note f˜ =
√
g˜. As (11) holds for f = y′(y−1) on (y0, lim
t→+∞
y(t)), we have
f ≡ f˜ and y∗ = lim
t→+∞
y(t). Thus, y can be determined from g˜ unambiguously.
Using x = Φ(y, y′) we conclude that the solution of (9) is unique. ⊓⊔
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Remark 4 Global existence needs additional hypotheses on F1 and F2. This
issue is not dealt with in the present work, as it is, first of all, disconnected
from the proof technique resulting from the parameter identification problem
and second easy to prove in the framework of the following applications.
As can be seen in (12), the following generalisation of (8) arises naturally from
the proof:
Definition 3 Suppose that F1 and F2 depend on some parameters (real num-













a generalised compatibility equation and by means of Theorem 2, this equation
defines an equivalence relation in the set of the admissible parameters Ψ .
4.2 Applications of Theorem 2
Gyllenberg-Webb model, µ > 0:
We have
P ′ = [b− ro(N)− ri(N)]P + ri(N)N, (13)
N ′ = (b+ µ)P − µN. (14)
Thus, F1(P,N) = [b− ro(N)− ri(N)]P + ri(N)N , F2(P,N) = (b+µ)P −µN ,
Φ(N,N ′) = N
′+µN
b+µ . Note that F2(P,N) > 0 is not true for all P > 0, N > 0,
but the uniqueness result applies if every solution satisfies F2(P (t), N(t)) >
0 ∀ t > 0. In their article, Gyllenberg and Webb presented cases where
the total tumour size N was not monotone, so we cannot hope to establish
F2(P (t), N(t)) > 0 for an arbitrary parameter set. However, starting from a
positive function f ∈ C1(N0, N∗), the generalised equivalence relation allows
us to specify which parameters are associated to N satisfying N ′ = f(N). Let
us be explicit:
f ′(n)f(n) = (b+ µ)
(











= f(n)(b− µ− ro(n)− ri(n)) + (bµ− µro(n) + bri(n))n.
Extended Gyllenberg-Webb model:
The proliferation term bP could be replaced by a nonlinear function ϕ(P,N) in
order to account for phenomena like angiogenesis or metastatic emission. For
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in a similar model. This extension reads (supposing µ = 0)
P ′ = ϕ(P,N)− [ro(N) + ri(N)]P + ri(N)N,
N ′ = ϕ(P,N).





, we easily see that Theorem 2 applies
with P = Φ(N,N ′) := N
′
1−(Nθ )
α , but one could imagine other examples, non-
linear in P , fitting into the framework of Theorem 2 as well.
Remark 5 The main results from Section 3 and Section 4 on the identifiability
of the Gyllenberg-Webb model can be summarised as follows. For arbitrary
functions (=observations) P and Q, if the total tumour size N = P + Q is
strictly increasing with N ′ > 0,
– either there are no passage rates ro and ri yielding P and Q,
– or N satisfies a compatibility equation (with µ = 0 or µ > 0) and there
are infinitely many passage rates ro and ri yielding P and Q.
5 Discussion
The parameter identifiability problem gives useful insights in the potential of
the Gyllenberg-Webb model. Under hypothesis (H), introduced in Section 3,
the model is able to reproduce any tumour growth model written as a first-
order ODE imposed on the total tumour size (cf. Corollary 1). If f is concave,
the passage rates can be chosen in a way that monotony (ro nondecreasing, ri
nonincreasing) holds. Consequently, the fact that Gyllenberg and Webb found
passage rates corresponding to scalar ODEs used as tumour growth models is
less a curiosity than an intrinsic property of their model in terms of flexibil-
ity. However, the non-uniqueness of corresponding parameters (cf. Figure 2)
shows that only the associated function in the compatibility equation can be
uniquely identified from the observations. If we want to identify the passage
rates ro and ri from P and Q, one of them has to be fixed in order to deter-
mine the other. Thus, the model leaves a latitude for the choice of parameters
corresponding to the associated function. Moreover, by using the explicit form
of the equivalence relation introduced in Definition 2, it has been shown that
even a finite dimension parameter estimation problem with simple shapes of
parametric functions can be ill-posed (cf. Corollary 2).
From a mathematical point of view, the particular form of the ODE system
permits a uniqueness proof in a case of non-Lipschitz parameters, though ad-
mittedly in a limited setting. The regularity of the ODE on N ′ and the fact
that N is strictly increasing play a crucial role as they allow to break the
problem down to a first-order ODE.
By posing µ = 0 in (H), a biologically significant setting can be taken into
account: Subcutaneous tumours often present a necrotic core trapped inside
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the tumour tissue, which thereby contributes to the total tumour volume. Ob-
viously, considering Q as the union of quiescent and dead cells introduces a
systematic error in the model: The passage rate Qri(N) should depend on
quiescent cells only. This error could be overcome by introducing a third cell
population D of dead cells, thereby augmenting the number of parameters.
However, SPECT imaging of proliferating cells does not permit to distinguish
quiescent and dead cells (total tumour size is only extrapolated from the pro-
liferating zone at the exterior). Therefore, µ = 0 is an acceptable compromise
in terms of applicability.
The techniques used for establishing the parameter equivalence relation can be
extended to a larger class of problems, including the Gyllenberg-Webb model
with µ > 0 and a variant with a nonlinear birth rate of proliferating cells. In
all cases, the increasing total tumour size is needed as a crucial assumption.
The generalisation allows to transfer all relevant results. In a setting where
most of the dead cells are eliminated by the immune system, the model with
µ > 0 might be the most adequate one. One could also imagine that the birth
rate bP of proliferating cells could be insufficiently described by a linear model.
Model choices can be founded on experimental validation, possibly in a murine
model using SPECT imaging.
In the present work, it has been established that the non-identifiability of
the passage rates is an intrinsic property in all of these models. For descrip-
tive purposes, the ill-posedness of the parameter identification problem is not
necessarily problematic. Any passage rate in a given equivalence class will de-
scribe not only global tumour growth (that is, N) in the same manner, but
also both proliferating and quiescent cells. However, if the effect of a therapy is
included in the model, the matter gets more delicate: The fact that quiescent
cells become proliferating again when a therapy is applied clearly shows that
the parameter equivalence cannot be true in this case, as ri ≡ 0 would not
include that effect but other passage rates in the same equivalence class, with a
strictly positive function ri, would. The real potential of the Gyllenberg-Webb
model can therefore only be tested when confronting it with experimental data
contrasting untreated and treated animals.
A pragmatic approach could exploit the non-identifiability of the passage rates:
First, the equivalence class is identified using the model without treatment.
Then, the data from the treated animals are used as an additional degree of
freedom for model calibration when adding a therapy. Its descriptive perfor-
mances can therefore be adapted to the quantity of data available.
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